RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
214 hedge funds and large institutions have $3.21B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2023 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 73 increasing their positions, 62 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
214
Holders Change
+9
Holders Change %
+4.39%
% of All Funds
3.37%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.13%
New
43
Increased
73
Reduced
62
Closed
33
Calls
$92.8M
Puts
$73.6M
Net Calls
+$19.2M
Net Calls Change
-$92.3M
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
$180M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
$107M |
| 3 |
Citadel Advisors
Miami,
Florida
|
$58.3M |
| 4 |
Holocene Advisors
New York
|
$68.1M |
| 5 |
Millennium Management
New York
|
$56.7M |
